Frontier Pharma Chronic, Acute and Neuropathic Pain Frontier Pharma Chronic, Acute and Neuropathic Pai | Page 5

5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic
Target Family 23
5.3 First-in-Class Pipeline Programs 23
5.4 First-in-Class and Established Pipeline Products by Pain Subtype 26
5.5 Table of All First-in-Class Pain Pipeline Products 30
6 Pain Pathophysiology and Innovation Alignment 32
6.1 The Complexity of Signaling Networks in the Central Nervous System 32
6.2 Matrix Assessment 32
7 First-in-Class Target and Pipeline Program Evaluation 35
7.1 Pipeline Programs Targeting Nerve Growth Factor and High Affinity Nerve Growth Factor
Receptor 35
7.2 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16 37
7.3 Pipeline Programs Targeting Bradykinin B1 Receptor 38
7.4 Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor 41
7.5 Pipeline Programs Targeting Purinoceptor 7 43
7.6 Pipeline Programs Targeting Metabotropic Glutamate Receptors 6 and 7 44
7.7 Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor 45
Follow Us: